Figure 1: A low cost, fully automated, user-friendly, lab on a chip genotyping analysis system (TPSA-003) predicting the risk of rashes by identifying DNA polymorphism markers (HLA-B*3505) that indicate a high correlation with the risk of drug rash occurrence, which is a side effect of the antiretroviral therapy, nevirapine.